IQVIA Holdings/$IQV
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About IQVIA Holdings
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
- Ticker
- $IQV
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 95,000
- Headquarters
- Durham, United States
- Website
- www.iqvia.com
IQVIA Holdings Metrics
BasicAdvanced
$43B
31.31
$8.25
1.16
-
Price and volume
Market cap
$43B
Beta
1.16
52-week high
$284.50
52-week low
$154.50
Average daily volume
1.4M
Financial strength
Current ratio
0.829
Quick ratio
0.74
Long term debt to equity
2.219
Total debt to equity
2.402
Interest coverage (TTM)
3.06%
Profitability
EBITDA (TTM)
3,118
Gross margin (TTM)
33.07%
Net profit margin (TTM)
8.05%
Operating margin (TTM)
13.89%
Effective tax rate (TTM)
15.37%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
5.08%
Return on equity (TTM)
21.39%
Valuation
Price to earnings (TTM)
31.308
Price to revenue (TTM)
2.497
Price to book
6.4
Price to tangible book (TTM)
-2.84
Price to free cash flow (TTM)
20.791
Free cash flow yield (TTM)
4.81%
Free cash flow per share (TTM)
12.43
Growth
Revenue change (TTM)
8.85%
Earnings per share change (TTM)
13.03%
3-year revenue growth (CAGR)
5.23%
10-year revenue growth (CAGR)
14.32%
3-year earnings per share growth (CAGR)
11.51%
10-year earnings per share growth (CAGR)
9.76%
What the Analysts think about IQVIA Holdings
Analyst ratings (Buy, Hold, Sell) for IQVIA Holdings stock.
Analyst projections of the future price of IQVIA Holdings stock.
Bulls say / Bears say
Clinical research demand is strengthening: second-quarter net new bookings climbed 19% to $3.15 billion, while the $34.2 billion R&D backlog includes $9.2 billion expected to convert to revenue over the next year. This supports visibility into near-term growth. (IQVIA)
IQVIA is expanding its AI-enabled commercial tools, launching Explorer in October to turn its proprietary data and analytics into faster, near-real-time decisions for clients. Wider adoption could create growth beyond traditional data services. (IQVIA)
The balance sheet remains highly geared: net debt was $14.1 billion and net leverage stood at 3.59 times adjusted EBITDA at the end of June. That limits financial flexibility if growth or cash generation disappoints. (IQVIA)
IQVIA recorded $114 million of restructuring costs in the first half and expects actions to continue into 2027 as it reduces overcapacity and integrates acquisitions. The ongoing adjustments add execution risk and near-term costs. (IQVIA)
A large backlog does not guarantee revenue: IQVIA says most contracts can be terminated at short notice and that it may lose or face delays in large client contracts. Delayed or cancelled work could slow backlog conversion and weaken the growth outlook. (IQVIA)
Data summarised monthly by Lightyear AI. Last updated on 18 Oct 2026.
IQVIA Holdings Financial Performance
Revenues and expenses
IQVIA Holdings Earnings Performance
Company profitability
Upcoming events
No upcoming events
IQVIA Holdings News
AllArticlesVideos
What IQVIA (IQV) Said on Its Q3 Earnings Call
MarketBeat7 days ago
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
Business Wire4 weeks ago
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
Business Wire4 weeks ago
Funds containing IQVIA Holdings
AllUSDEURGBP
Fund name | Fund size | $IQV weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 1.67% |
iShares Healthcare Innovation€2B78 | $1.2B | 1.67% |
iShares Healthcare Innovation$HEAL | $1.3B | 1.67% |
iShares MSCI World Health Care Sector Advanced€CBUF | $683M | 0.97% |
iShares MSCI World Health Care Sector Advanced£WHCA | $362M | 0.97% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.